T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu\u2019nun\u00a0 (T\u00dcB\u0130TAK) programlar\u0131na en \u00e7ok proje ba\u015fvurusu yapan ve projesi en \u00e7ok kabul g\u00f6ren \u00fcniversite olan Ege \u00dcniversitesi (E\u00dc), yeni projelerle ba\u015far\u0131s\u0131n\u0131 s\u00fcrd\u00fcrmeye devam ediyor.<\/p>\n
Y\u00fcr\u00fct\u00fcc\u00fcl\u00fc\u011f\u00fcn\u00fc Ege \u00dcniversitesi Eczac\u0131l\u0131k Fak\u00fcltesi Farmakoloji Anabilim Dal\u0131 Doktora \u00d6\u011frencisi Beste Yurdacan Ya\u015far\u2019\u0131n yapt\u0131\u011f\u0131 “Huh7 H\u00fccrelerinde Sorafenib Direncini Geri \u00c7evirmede Yeni Bir Tedavi Hedefi: Depo Kontroll\u00fc Kalsiyum Giri\u015fi” ba\u015fl\u0131kl\u0131 proje T\u00dcB\u0130TAK 1002 H\u0131zl\u0131 Destek Program\u0131 kapsam\u0131nda desteklenmeye uygun bulundu.<\/p>\n
Ege \u00dcniversitesi Rekt\u00f6r\u00fc Prof. Dr. Necdet Budak, Egeli akademisyenler taraf\u0131ndan y\u00fcr\u00fct\u00fclen projelerin T\u00dcB\u0130TAK nezdinde kabul g\u00f6rmesinin sevindirici oldu\u011funu belirterek, \u201cAkademisyenlerimizin \u00f6zverili \u00e7al\u0131\u015fmalar\u0131 ile her y\u0131l T\u00dcB\u0130TAK\u2019a en \u00e7ok proje ba\u015fvurusu yapan ve en \u00e7ok projesi kabul g\u00f6ren \u00fcniversite olman\u0131n gururunu ya\u015f\u0131yoruz. Ege \u00dcniversitesi olarak ara\u015ft\u0131ran, proje \u00fcreten t\u00fcm akademisyenlerimizin her zaman destek\u00e7isi olmaya devam edece\u011fiz. Projesi kabul g\u00f6ren ara\u015ft\u0131rmac\u0131lar\u0131m\u0131z\u0131 kutluyor, ba\u015far\u0131lar\u0131n\u0131n devam\u0131n\u0131 diliyorum\u201d dedi.<\/p>\n
Ara\u015ft\u0131rman\u0131n i\u00e7eri\u011fi ile ilgili bilgi veren Prof. Dr. Yasemin Era\u00e7, \u201cHepatosel\u00fcler karsinoma kansere ba\u011fl\u0131 meydana gelen \u00f6l\u00fcmlerin ikinci \u00f6nde gelen nedenidir ve genellikle kronik karaci\u011fer hastal\u0131klar\u0131 zemininde ortaya \u00e7\u0131kmaktad\u0131r. Erken evre hepatosel\u00fcler karsinomada cerrahi tedaviler uygulanabilse de hastalar\u0131n yakla\u015f\u0131k y\u00fczde 50’si hastal\u0131\u011f\u0131n ileri evrelerinde tan\u0131 almaktad\u0131r. \u0130leri evre hepatosel\u00fcler karsinoman\u0131n sistemik tedavisinde kullan\u0131lan sorafenib ile tedavi edilen hastalar\u0131n yakla\u015f\u0131k y\u00fczde 30’u sorafenibden fayda g\u00f6rmektedir ve bu hasta grubu genellikle 6 ay i\u00e7inde ilaca diren\u00e7 kazanmaktad\u0131r. Diren\u00e7 geli\u015fimi sonucunda hastalarda tedavi ba\u015far\u0131s\u0131 d\u00fc\u015fmekte ve sa\u011fkal\u0131m azalmaktad\u0131r. Bu nedenle tedavi s\u00fcresince ilaca kar\u015f\u0131 geli\u015fen diren\u00e7 mekanizmalar\u0131n\u0131n ayd\u0131nlat\u0131lmas\u0131 direncin \u00f6nlenmesi-geciktirilmesi, ila\u00e7 tedavisinden sa\u011flanan yarar\u0131n s\u00fcrd\u00fcr\u00fclmesi, tedavinin ba\u015far\u0131s\u0131 ve sa\u011fkal\u0131m a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r. Proje kapsam\u0131nda g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 giderek artan hepatosel\u00fcler karsinomada geli\u015fen sorafenib direncinin geli\u015fiminde yeni bir tedavi hedefi olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fc\u011f\u00fcm\u00fcz depo kontroll\u00fc kalsiyum kanallar\u0131n\u0131n rol\u00fc ara\u015ft\u0131r\u0131lmaktad\u0131r\u201d dedi.<\/p>\n
Ege \u00dcniversitesi Eczac\u0131l\u0131k Fak\u00fcltesi Farmakoloji Anabilim Dal\u0131 Doktora \u00d6\u011frencisi Beste Yurdacan Ya\u015far\u2019\u0131n y\u00fcr\u00fct\u00fcc\u00fcl\u00fc\u011f\u00fcn\u00fc yapt\u0131\u011f\u0131 projede Prof. Dr. Yasemin Era\u00e7 dan\u0131\u015fman olarak g\u00f6rev al\u0131yor.<\/p>\n","protected":false},"excerpt":{"rendered":"
T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu\u2019nun\u00a0 (T\u00dcB\u0130TAK) programlar\u0131na en \u00e7ok proje ba\u015fvurusu yapan ve projesi…<\/p>\n","protected":false},"author":2,"featured_media":20169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,99,1],"tags":[],"class_list":["post-20168","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilim","category-egitim","category-gncl"],"featured_image_urls":{"full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-scaled.jpg",2560,1875,false],"thumbnail":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-150x150.jpg",150,150,true],"medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-300x220.jpg",300,220,true],"medium_large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-768x562.jpg",640,468,true],"large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-1024x750.jpg",640,469,true],"1536x1536":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-1536x1125.jpg",1536,1125,true],"2048x2048":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-2048x1500.jpg",2048,1500,true],"newsphere-slider-full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-1280x720.jpg",1280,720,true],"newsphere-featured":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-1024x750.jpg",1024,750,true],"newsphere-medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2024\/03\/BESTE-YURDACAN-YASAR-Necdet-Budak-Prof.-Dr.-Yasemin-Erac-720x380.jpg",720,380,true]},"author_info":{"display_name":"Editor","author_link":"https:\/\/www.euegeajans.com\/index.php\/author\/editor\/"},"category_info":"Bilim<\/a> E\u011fitim<\/a> G\u00fcncel<\/a>","tag_info":"G\u00fcncel","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/20168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/comments?post=20168"}],"version-history":[{"count":1,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/20168\/revisions"}],"predecessor-version":[{"id":20170,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/20168\/revisions\/20170"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media\/20169"}],"wp:attachment":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media?parent=20168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/categories?post=20168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/tags?post=20168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}